GIF withdraws one batch of anticoagulant Zarixa 20 mg from pharmacies across Poland
The Chief Pharmaceutical Inspector has withdrawn one batch of Zarixa 20 mg from sale. The drug is used, among other things, in patients with atrial fibrillation. The decision takes effect immediately and is based on irregularities in verifying the authenticity of packaging.

In brief
- Główny Inspektor Farmaceutyczny wycofał z obrotu jedną serię leku Zarixa 20 mg z natychmiastową wykonalnością.
- Powodem są nieprawidłowości w systemie weryfikacji autentyczności opakowań, ujawnione po reklamacji hurtowni.
- Wycofanie dotyczy serii 374020026 o terminie ważności 09.2029, pakowanej po 28 kapsułek.
Inspector's decision and sales ban
The Chief Pharmaceutical Inspector issued a decision on November 20, 2026, to withdraw Zarixa 20 mg from sale. The specified batch may no longer be sold or dispensed to patients, and it may not be placed back on the market (Pilny komunikat GIF. Popularny lek przeciwzakrzepowy wycofany z aptek. Sprawdź numer serii – fakt.pl) (GIF pilnie wycofuje ważny lek w całej Polsce. Sprawdź numer serii na opakowaniu – wprost.pl). The decision takes immediate effect, meaning wholesalers and pharmacies must withdraw the product without waiting for the decision to become final (GIF wycofuje serię leku przeciwzakrzepowego. Decyzja obejmuje ponad 20 tys. opakowań – GazetaPrawna.pl).
Reason for the withdrawal
According to the GIF, the cause is serious irregularities in the system for verifying packaging authenticity. The problem came to light after a complaint from one of the wholesalers.
Which packages to check
The decision covers hard capsules of Zarixa 20 mg, packed in 28-count packs and manufactured by Celon Pharma S.A. Only one batch is affected: number 374020026, with an expiry date of 09.2029. The GTIN is 05909991528607. A patient who has this medicine at home should first compare the batch number and expiry date with the details in the notice. Other batches are not covered by the decision.
Who this affects
Zarixa contains rivaroxaban, a substance that reduces blood clotting. The drug is used in patients with atrial fibrillation to lower the risk of stroke, and in treating deep vein thrombosis and pulmonary embolism. People taking this preparation should not stop it on their own without consulting a doctor. Therapy safety requires this, and the batch number applies only to the sale and dispensing of the product.
Sources
- #Zarixa
- #Rivaroxaban
- #GIF
- #DrugRecall
- #CelonPharma
- #Anticoagulant
- #Rywaroksaban
- #WycofanieLeku
- #LekPrzeciwzakrzepowy
Story graph
Connected stories
GIF withdraws one batch of anticoagulant Zarixa 20 mg from pharmacies across Poland
The Chief Pharmaceutical Inspector has withdrawn one batch of Zarixa 20 mg from sale. The drug is used, among other things, in patients with atrial fibrillatio…